US News

U.S. secures GSK-Vir COVID-19 antibody drug doses worth $1 billion

Published by

By Pushkala Aripaka (Reuters) -The United States has signed contracts worth about $1 billion to secure the antibody-based COVID-19 treatment developed by Britain’s GSK and U.S. based Vir Biotechnology, the drugmakers said on Wednesday. GSK said the deal brought the total number of doses secured for the treatment, sotrovimab, to more than 750,000 globally, adding that supply was expected by Dec. 17. The United States would have an option to buy additional doses through March 2022. The companies did not specify how many doses the U.S. government had signed up for. However, other deals include 10…

Read More

Facebook Comments

Check Also

Tens of thousands protest in Austria against Covid vaccine mandate

Published by DPA A total of almost 40,000 ...